Evidence map›Paper›PMID 40646076›Full record

ArticleScientific reports2025

Evaluating breast cancer screening performance without registries using medico-administrative data.

Emilien Jemelen, Francisco Orchard, William Madie, Bernard Valentin, Josine Belin, Enora Laas, Guillaume Jeannerod, Pierre Mares, Sandrine Katsahian, Agathe Guilloux

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emilien JemelenFrench Institute for Research in Computer Science and Automation (INRIA), Paris, France. emilien.jemelen@inria.fr.
Francisco OrchardData Science Department, Epiconcept, Paris, France.
William MadieData Science Department, Epiconcept, Paris, France.
Bernard ValentinRegional Coordination Center for Cancer Screening (CRCDC), Nîmes, France.
Josine BelinRegional Coordination Center for Cancer Screening (CRCDC), Nîmes, France.
Enora LaasInstitut Curie, Foundation for Cancer Research, Paris, France.
Guillaume JeannerodEpiconcept, Paris, France.
Pierre MaresRegional Coordination Center for Cancer Screening (CRCDC), Nîmes, France.
Sandrine KatsahianGeorges Pompidou European Hospital, Paris, France.
Agathe GuillouxFrench Institute for Research in Computer Science and Automation (INRIA), Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The French Breast Cancer Screening Program (DOCS) was created to detect early Breast Cancer (BC). Key performance indicators for digital mammography include sensitivity (SE), positive predictive value (PPV), interval cancer rate (ICR) and cancer detection rate (CDR). Calculating these metrics requires a linkage between screening data and BC registries; however, registries are scarce in France and often inaccessible for research. We therefore used medico-administrative data as an alternative. We linked regional screening data to the French National Health Data System (SNDS) between 2011 and 2020. Women were followed for 24 months post-screening. Screen-detected cancers and those identified with the SNDS were included. Performance metrics were calculated based on these linked datasets. A total of 252,786 screening exams were analyzed, covering 29,661-33,447 screenings annually, with a mean age of 61 years. SE was 77.9% (95% CI 76.3-79.3), indicating that approximately four in five cancers were detected through mammography. PPV was 19.8% (95% CI 19-20.5), meaning that one in five women with a positive screening test were confirmed with cancer within 24 months. CDR was 10.9 per 1000 exams (95% CI 10.5-11.3), equating to one detected case per 100 screenings. ICR was 2.4 per 1000 exams (95% CI 2.2-2.6), meaning that more than two interval cancers were detected per 1000 screenings. This identification approach using medico-administrative data offers a reproducible alternative for regions where cancer registries are unavailable. A future study applying this methodology in a registry-covered region could further validate the effectiveness of linking screenings to SNDS data for systematic cancer identification.

Indexed as

Breast NeoplasmsEarly Detection of CancerMass ScreeningAdultAgedFemaleFranceHumansMammographyMiddle AgedRegistriesCancer registriesData linkageEuropean health policyFull-field digital mammography (FFDM)Interval cancer rateOrganized breast cancer screeningPerformance assessmentSNDS (National Health Data System) administrative data

Identifiers

PMID40646076
PMCPMC12254203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.